文献速递消化系统肿瘤

手术与消融治疗肝细胞癌:随机对照试验(SURF-RCT)与非随机前瞻性观察试验(SURF-Cohort)

Surgery Versus Ablation for Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF-RCT Trial) and a Nonrandomized Prospective Observational Trial (SURF-Cohort Trial).
PubMed 文献 · J Clin Oncol · 2025-06-24

SURF-RCT随机对照试验比较手术与射频消融治疗≤3 cm、≤3个结节的肝细胞癌,5年总生存率手术组74.6% vs 消融组70.4%(HR 0.96,校正P=0.84),无复发生存率42.9% vs 42.7%(HR 0.90,校正P=0.84),未显示手术优于消融。同期SURF-Cohort观察试验经逆概率加权后两结局无显著差异。

要点

  • SURF-RCT中手术组5年OS 74.6% vs RFA组70.4%(HR 0.96,校正P=0.84)。
  • SURF-RCT中手术组5年RFS 42.9% vs RFA组42.7%(HR 0.90,校正P=0.84)。
  • SURF试验未证明手术对小肝癌优于射频消融。

核心结论

  • SURF试验未能证明手术对小肝癌的疗效优于射频消融。

研究设计与样本

  • SURF-RCT为随机对照试验,SURF-Cohort为非随机前瞻性观察试验,均在日本的49家机构开展。
  • 纳入标准为最大肝细胞癌直径≤3 cm且结节数≤3个。
  • 共同主要终点为无复发生存期和总生存期。
  • 2009年至2015年共注册1094例患者,排除不合格者后SURF-RCT纳入302例(手术组150例,RFA组152例),SURF-Cohort纳入753例(手术组382例,RFA组371例)。

主要发现

  • SURF-RCT中90%的患者为单发肝细胞癌,约65%的患者肿瘤直径≤2.0 cm。
  • SURF-RCT中严重不良事件发生率手术组为3.3%,RFA组为0%。
  • SURF-RCT中5年总生存率手术组74.6% vs RFA组70.4%(HR 0.96;校正P=0.84)。
  • SURF-RCT中5年无复发生存率手术组42.9% vs RFA组42.7%(HR 0.90;校正P=0.84)。
  • SURF-Cohort中基线因素组间不平衡,经逆概率加权分析后总生存期和无复发生存期均无显著差异(P=0.77和P=0.08)。

关键数值与推荐

  • SURF-RCT中手术组86例复发,其中14例(16.3%)接受手术、50例(58.1%)接受RFA。
  • SURF-RCT中RFA组95例复发,其中8例(8.4%)接受手术、55例(57.9%)接受RFA。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We conducted a randomized controlled trial (SURF-RCT) to evaluate the efficacy of surgery versus radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Simultaneously, eligible patients who dissented from random assignment were enrolled in a nonrandomized prospective observational trial (SURF-Cohort). We aimed to report the final analyses of overall survival (OS) and updated recurrence-free survival (RFS) in the SURF-RCT and SURF-Cohort trials. METHODS: The trials were conducted in 49 institutions in Japan. Patients with a largest HCC diameter of ≤3 cm and ≤3 HCC nodules were eligible. The co-primary end points were RFS and OS. RESULTS: During 2009-2015, 1,094 patients were registered. After excluding ineligible patients, 302 and 753 patients were included in the SURF-RCT (surgery, n = 150; RFA, n = 152) and SURF-Cohort trial (surgery, n = 382; RFA, n = 371), respectively. In the SURF-RCT trial, 90% of patients had solitary HCC, and approximately 65% had an HCC diameter of ≤2.0 cm. Serious adverse effects occurred in 3.3% of the surgery group and none in the RFA group. The 5-year OS was 74.6% in the surgery group and 70.4% in the RFA group (hazard ratio [HR], 0.96; adjusted P = .84). The 5-year RFS was 42.9% in the surgery group and 42.7% in the RFA group (HR, 0.90; adjusted P = .84). In the surgery group, 86 patients had recurrences; 14 (16.3%) underwent surgery, and 50 (58.1%) underwent RFA. In the RFA group, 95 patients had recurrences; 8 (8.4%) underwent surgery, and 55 (57.9%) underwent RFA. In the SURF-Cohort trial, baseline factors were imbalanced between groups. After adjusting with the inverse probability of treatment weighting analysis, OS and RFS showed no significant difference (P = .77 and P = .08). CONCLUSION: The SURF trial did not demonstrate that surgery was superior to RFA for small HCC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kawaguchi Y, Hasegawa K, Kashiwabara K, et al. Surgery Versus Ablation for Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF-RCT Trial) and a Nonrandomized Prospective Observational Trial (SURF-Cohort Trial). J Clin Oncol. 2025. PMID: 40554738. doi:10.1200/JCO-24-02030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。